e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Defi Technologies, Inc. - Common Stock
Electrovaya Inc
Reliance Global Group, Inc. - Common Stock
Sbi Holdings Inc Ord
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by IGI, Inc.
Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors
November 17, 2026
From
IGI, Inc.
Via
GlobeNewswire
Ichnos Glenmark Innovation (IGI) to Present Updated Clinical Data for ISB 2001 (ABBV-2001) in Relapsed/Refractory Multiple Myeloma at 68th ASH Annual Meeting
November 04, 2026
From
IGI, Inc.
Via
GlobeNewswire
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
June 23, 2026
From
IGI, Inc.
Via
GlobeNewswire
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
May 20, 2026
From
IGI, Inc.
Via
GlobeNewswire
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
July 10, 2025
From
IGI, Inc.
Via
GlobeNewswire
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
June 02, 2025
From
IGI, Inc.
Via
GlobeNewswire
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
May 05, 2025
From
IGI, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.